You can brush medical insurance!The first domestic new crown special medicine has been temporarily included in the payment scope of the medical insurance fund

A few days ago, China's first new coronal virus neutralized antibody combined therapy drugs -the new crown and antibody Ambarab and Romi Siwei's combination therapy in the country have arrived in Shenzhen Third People's Hospital and began to be clinically clinically. Use. The reporter learned from the Shenzhen Medical Insurance Bureau on July 16 that this new crown special medicine has been temporarily included in the payment scope of the medical insurance fund to ensure that patients do not affect medical treatment due to expenses.

It is understood that the dosage of the drug used dosage of Anbawei's anti -anti -anti -antibiotic therapy is the highest dose among all approved neutralized antibodies at home and abroad. Against 1000 mg and Lemis Weimab are composed of 1000 mg. The method of vein output is lost in one hour. It is enough to hit it once. It does not need to be treated again.

At present, the domestic listing model of Ambellimab and Romi Siwei's combination therapy has adopted an independent pricing model in China. Overseas, the business model of this drug is a government procurement model. For example, at the scale of the US government's procurement of millions of people, the government procurement price per person is $ 1,500 to 2,000. In China, the pricing price of this domestic new crown special drug is lower than the US procurement price, which is basically within 10,000 yuan.

10,000 yuan is a heavy burden for some families, but the good news is that this drug patient can take medical insurance settlement. The Shenzhen Medical Insurance Bureau stated that during the epidemic, drugs, diagnosis and treatment items and medical consumables used suspected and diagnosed with new coronary virus infections, in line with the "New Coronary Virus Pneumonia Diagnosis and Treatment Plan (Trial Ninth Edition)", all temporarily included in medical insurance Fund payment scope, cancel the standards of hospitalization, to ensure that patients do not affect medical treatment due to expenses. Anbawei's anti -anti -anti -anti -anti -anti -anti -anti -counterfeit combination therapy has been included in the "New Coronatte Pneumonic Pneumonia Diagnosis Plan (Trial Ninth Edition)", so the medical insurance fund is paid in accordance with regulations.

Regarding the definition of "temporarily incorporated in the payment scope of the medical insurance fund", the Shenzhen Medical Insurance Bureau explained that considering the particularity of the development of the new crown pneumonia, in order to ensure that the new crown patients do not affect the medical treatment due to expenses, the National Medical Insurance Administration will confirm the suspected and confirmed the new coronary virus to confirm the diagnosis of the new coronary virus. Infected pneumonia patients adopt special reimbursement policies. Pharmaceuticals that conform to the new coronary virus infection formulated by the health and health department can be temporarily incorporated into the scope of the medical insurance fund payment. It is not restricted by the adjustment of the medical insurance catalog, ensuring that all new crown patients can get timely and effective treatment. At present, the "New Coronatte Pneumonic Pneumonia Diagnosis and Treatment Plan (Trial Ninth Edition)". Except for Anbawei's monoclonal anti -anti -anti -anti -resistance, other drugs in the diagnosis plan can be reimbursed through medical insurance.

Source ｜ Jingbao APP

Reporter: Rodin

- END -